Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2002

View Archived Issues

Three ZymoGenetics product candidates to enter clinic in the next year

Good safety profile reported for IL-13-PE38QQR in malignant glioma

Potential use of gabapentin in glossodynia

Neuroprotective effects reported for zanapezil in ischemic rats

Potential use of NO-releasing hydrogel dressing in wound healing

Induction of Th2 responses reported for rhIL-4 in psoriatic patients

Novel series of HIV reverse transcriptase inhibitors identified at Pfizer

Merck designs new NK1 antagonists

New amlodipine analogue with utility in angina and hypertension

Aeolus and Duke University claim porphyrin-based antioxidants for pulmonary inflammatory diseases

Novel ligands of G-protein-coupled receptors covered by Sepracor patent

Lilly and Boehringer Ingelheim sign cocommercialization agreements for duloxetine

Millennium to submit Velcade NDA and MAA filings by early 2003

huN901-DM1 enters phase II portion of U.S. SCLC study

Curis licenses PYY patents to Amylin for treatment of metabolic diseases

First phase III alvimopan trial in postoperative ileus completes enrollment

More obstacles to Pfizer/Pharmacia merger removed

Orphan drug status sought for thymosin beta 4

RSD-1235 shows oral bioavailability in humans

Once-weekly dosing of Enbrel supported by phase III study

IL-15-targeting antibody superior to ciclosporin in mouse model of psoriasis

Efalizumab suppresses inflammation-related genes in addition to T-cell migration

Civacir receives orphan drug status for prevention of hepatitis C

FDA requests additional clinical data for lercanidipine

Epimmune files IND for cancer vaccine

Novo Nordisk submits NDA for NN-304

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...